Usually, research takes time and patience — here are some tips for cultivating patience. Graphic by Miguel Tovar/University of Houston

Aristotle, one of the most famous philosophers and scientists of all time, once said, "Patience is bitter, but its fruit is sweet."

What the phrase conveys is all too familiar to those in the scientific community. Patience needs to be cultivated by researchers who wait for the outcome of their studies. History is full of success stories of the science community showing both patience and persistence.

Quitters never prosper

Patience is essentially the ability to stay relatively unruffled in the face of adversity. Earning a Ph.D. takes time, writing grants and getting funding takes time, and experiments – some of them never yield results or take a long time to do so.

For example, there is the story of the two scientists who discovered the HPV virology, which eventually led to routine tests that check for cervical cancer in women. They were studying and researching the bacteria that causes the HPV virus for nearly 13 years before their findings were accepted. "In January 1928, Dr. George N. Papanicolaou first announced his findings at the Third Race Betterment Conference in Battle Creek, Michigan, but these were met with skepticism and resistance from the scientific community. This rejection did not deter Dr. Papanicolaou from continuing his research in this field in 1939, until eventually his findings were published on March 11, 1941," wrote Ioannis N. Mammas and Demetrios A. Spandidos in Experimental and Therapeutic Medicine.

This is by no means the only example – many researchers face setbacks and long experimentation periods that seemingly go nowhere, making any outcome at all even more sacred.

A marshmallow now…

A new study by Adrianna Jenkins, a UC Berkeley postdoctoral researcher, and Ming Hsu, an associate professor of marketing and neuroscience at UC Berkeley's Haas School of Business, is making headway in determining whether willpower is actually the way one overcomes adversity or if patience is born of something else. We know the famous marshmallow test, where young children were told they could have one marshmallow right away or two marshmallows if they waited a short time. Thirty years later, the children with better impulse control were more successful than their counterparts who had little self-control.

The newer study works like this: "The actual reward outcomes were identical, but the way they were framed differed. For example, under an "independent" frame, a participant could receive $100 tomorrow or $120 in 30 days. Under a "sequence" frame, a participant had to decide whether to receive $100 tomorrow and no money in 30 days or no money tomorrow and $120 in 30 days." More on this later.

As one might guess, the ones who showed delayed gratification were the ones using their imaginations the most: "Participants in the sequence frame reported imagining the consequences of their choices more than those in the independent frame. One participant wrote, 'It would be nice to have the $100 now, but $20 more at the end of the month is probably worth it because this is like one week's gas money.''

Willing yourself patient?

So how does willpower play into the equation? "Whereas willpower might enable people to override impulses, imagining the consequences of their choices might change the impulses," Jenkins says. "People tend to pay attention to what is in their immediate vicinity, but there are benefits to imagining the possible consequences of their choices."

Researchers may not think of themselves as particularly creative, but an imagination is definitely needed to frame hypotheses and conduct experiments, so one could argue that scientists are perhaps some of the most creative, imaginative people around.

The Big Idea

Waiting is still a drag, right?

In The Greater Good, a University of California – Berkeley science magazine, there were three concrete steps to help your research become even more fulfilling and make you more patient as an investigator: mindfulness, reframing the situation and being grateful.

First, mindfulness. Mindfulness techniques include things as simple as acknowledging you are overwhelmed or frustrated with a co-PI. It lets you deal better and leads to the second step, which is reframing the situation in a positive light. And, remember the $120 scenario? Those who were grateful for the amount of money they were receiving did better at delaying gratification, according to the study.

So, when you're working on your latest research, don't forget to practice patience. The fruits will taste even sweeter once the obstacles are endured, one by one.

------

This article originally appeared on the University of Houston's The Big Idea. Sarah Hill, the author of this piece, is the communications manager for the UH Division of Research.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."